囊蛋白酶B抑制剂在莱什曼病治疗中的进展
Ana Luisa Rodriguez Gini1, Emilio Emilio João1, Juliana Romano Lopes1
1Department of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, SP, Brazil.
Current drug targets
|October 1, 2024
概括
像CPB这样的氨酸蛋白酶是Leishmania寄生虫的关键毒性因素. 本综述强调了利什曼病治疗的有希望的非和药物候选药物,有助于合理的抑制剂设计.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 来自Leishmania* spp. 的氨酸蛋白酶. 它们是调节宿主免疫反应的关键毒性因素.
- 这些蛋白酶是开发针对莱什曼病的新型治疗干预措施的重要目标.
- 囊蛋白酶B (CPB) 在寄生虫的生存和发病过程中起着重要的作用.
研究的目的:
- 审查从2001年到2024年针对莱什曼病的氨酸蛋白酶药物发现的进展.
- 为了分析囊蛋白酶抑制剂的药用化学景观.
- 确定有前途的非性和性化合物进行进一步的研究.
主要方法:
- 对抗 *Leishmania* 寄生虫的囊蛋白酶抑制剂的文献综述.
- 使用pkCSM进行计算分析,以评估物理化学性质和药物相似性.
- 使用解离常数 (Ki) 和半最大抑制度 (IC50) 值来评估化合物功效.
主要成果:
- 非类化合物 (69.2%) 和类药物 (30.8%) 被确定为潜在的抑制剂.
- 显著比例的非性化合物 (41.7%为Ki, 80.0%为IC50) 显示出高强度 (<1μM).
- 所有评估的化合物都显示出高强度 (43.8%的Ki,31.3%的IC50<1μM).
结论:
- 基于非和的化合物都显示出作为治疗莱什曼病的治疗剂的前景.
- 特定的化合物 (非性: 1, 2, 4; 性: 48-52) 需要进一步的结构-活性关系研究.
- 向囊蛋白酶仍然是开发新型抗莱什曼药物的可行策略.
更多相关视频
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


